Chimeric Antigen Receptor Therapy for B-cell Malignancies
<p>We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.</p>
Main Author: | David L Porter, Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June |
---|---|
Format: | Article |
Language: | English |
Published: |
Ivyspring International Publisher
2011-01-01
|
Series: | Journal of Cancer |
Online Access: | http://www.jcancer.org/v02p0331.htm |
Similar Items
-
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
by: Michael M. Boyiadzis, et al.
Published: (2018-12-01) -
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01) -
Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors
by: Yashang Zheng, et al.
Published: (2024-06-01) -
Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies
by: Faizan Ahmad
Published: (2020-01-01) -
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
by: Zhihuan Yang, et al.
Published: (2023-10-01)